November 19, 2019. If FDA approves abuse deterrent formulations, the label should clearly describe the exact property demonstrated in studies.
Read More »On Medical Treatments & Products
NCHR Testimony on Research Needed on Immunological Responses to Metal in Implants
November 13, 2019. Dr. Diana Zuckerman describes the types of research needed to reduce harm from the metal and other substances in implanted devices, including joint replacements, cardiac implants, mesh, reproductive devices, and many other types of implants.
Read More »NCHR Testimony on Empagliflozin to Improve Glycemic Control
November 13, 2019. The data on Empagliflozin for managing Type 1 Diabetes is limited and it is not clear if the small improvement seen in the clinical trial is clinically meaningful for patients.
Read More »NCHR Testimony on Vascepa to Reduce Risk for Cardiovascular Events
November 14, 2019. Drugs to help reduce the risk of cardiovascular events save lives. The REDUCE-IT study provides encouraging data that AMR101 [Vascepa (icosapent ethyl) ] may help, but there are some important concerns that must be addressed before approval.
Read More »NCHR’s Comments on the USPSTF’s Recommendation on Screening for Bacterial Vaginosis in Pregnant Persons
November 4, 2019. Given the lack of convincing evidence that screening for bacterial vaginosis leads to a clinical benefit, NCHR supports the USPSTF’s caution in making a recommendation to screen for bacterial vaginosis in pregnant persons to prevent preterm delivery.
Read More »